{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":7,"x_thread":5,"youtube":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04778397\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ENHANCE-2","nct_id":"NCT04778397","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=enhance-2-nct04778397. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ENHANCE-2","arms":[{"description":"Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.","label":"Magrolimab + Azacitidine","type":"EXPERIMENTAL"},{"description":"Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.","label":"Control Arm: Venetoclax + Azacitidine","type":"ACTIVE_COMPARATOR"},{"description":"Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.","label":"Control Arm: 7+3 Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-03-25","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia"],"enrollment":{"count":258,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Magrolimab","type":"DRUG"},{"name":"Venetoclax","type":"DRUG"},{"name":"Azacitidine","type":"DRUG"},{"name":"Cytarabine","type":"DRUG"},{"name":"Daunorubicin","type":"DRUG"},{"name":"Idarubicin","type":"DRUG"},{"name":"Steroidal Eye Drops","type":"DRUG"}],"last_update":"2025-02-05","lead_sponsor":"Gilead Sciences","official_title":"A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-03-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy","timeFrame":"Up to 2.1 years"}],"references":[{"citation":"Zeidner JF, Sallman DA, Recher C, Daver NG, Leung AYH, Hiwase DK, Subklewe M, Pabst T, Montesinos P, Larson RA, Wilde L, Enjeti AK, Kawashima I, Papayannidis C, O'Nions J, Johnson L, Dong M, Huang J, Bagheri T, Hacohen Kleiman G, Lee C, Vyas P. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31;146(5):590-600. doi: 10.1182/blood.2024027408.","pmid":"40009500","type":"DERIVED"},{"citation":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 Nov 1;41(31):4893-4904. doi: 10.1200/JCO.22.02604. Epub 2023 Sep 13.","pmid":"37703506","type":"DERIVED"}],"start_date":{"date":"2021-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","url":"https://clinicaltrials.gov/study/NCT04778397"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/enhance-2-nct04778397"}